PPBT.US Purple Biotech

Healthcare Biotechnology USA Stocks
1.71 USD
Close of Nov 18, 2026
0.9100 8.90
Market cap
USD 2.78M
P/E
-
P/B
0.22x
ROE
5.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PPBT.US undervalued?

Graham number

The Graham number of Purple Biotech cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Purple Biotech fundamental analysis

No fundamental analysis for Purple Biotech yet.

Purple Biotech stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarc…

Full company profile